Establishment and application of a predictive model for gefitinib-induced severe rash based on pharmacometabolomic profiling and polymorphisms of transporters in non-small cell lung cancer
Shaoxing Guan,Xi Chen,Shuang Xin,Shu Liu,Yunpeng Yang,Wenfeng Fang,Yan Huang,Hongyun Zhao,Xia Zhu,Wei Zhuang,Fei Wang,Wei Feng,Xiaoxu Zhang,Min Huang,Xueding Wang,Li Zhang
DOI: https://doi.org/10.1016/j.tranon.2020.100951
IF: 4.803
2021-01-01
Translational Oncology
Abstract:A total of 346 patients were enrolled in this study.Severe rash (grade 3&4) did not gain more bonification compare to grade 1&2 rash.Gefitinib and its four metabolites were detected in patients' plasma.A specific and sensitive predictive model were established based on pharmacometabolomic profiling and pharmacogenomics approach.Rash is a well-known predictor of survival for patients with gefitinib therapy with non-small cell lung cancer (NSCLC). However, whether patients with more severe rash obtain the more survival benefits from gefitinib is still unknown, and predicted model for severe rash is needed.The relationship between gefitinib-induced rash and progression free survival (PFS) was primarily explored in the retrospective cohort. The association between rash and gefitinib/metabolites concentration and genetic polymorphisms were determined by pharmacometabolomic and pharmacogenomics methods in the exploratory cohort and validated in an external cohort.The survival for patients with rash was significantly higher than that of patients without rash (<em>p</em> = 0.0002, <em>p</em> = 0.0089), but no difference was found between grade 1/2 or grade 3/4. Only the concentration of gefitinib, but not its metabolites, was found to be associated with severe rash, and the cutoff value of gefitinib was 204.6 ng/mL conducted by ROC curve analysis (AUC=0.685). A predictive model for severe rash was established: gefitinib concentration (OR = 11.523, 95% CI = 2.898-64.016, <em>p</em> = 0.0016), <em>SLC22A8</em> rs4149179(CT vs CC, OR = 3.156, 95% CI = 0.958–11.164, <em>p</em> = 0.0629), <em>SLC22A1</em> rs4709400(CG vs CC, OR = 10.267, 95% CI = 2.067–72.465, <em>p</em> = 0.0087; GG vs CC, OR = 5.103, 95% CI = 1.032–33.938, <em>p</em> = 0.061). This model was confirmed in the validation cohort with an excellent predictive ability (AUC = 0.749, 95% CI = 0.710–0.951).Our finding demonstrated that the incidence, not the severity, of gefitinib-induced rash predicted improved survival, the gefitinib concentration and polymorphisms of <em>SLC22A8</em> and <em>SLC22A1</em> were recommended to manage severe rash.
oncology